Kymera Therapeutics, Inc. (KYMR) stock
KYMRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/30227% above fair value
$121.52−4.33 (-3.44%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Kymera Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Kymera Therapeutics's R&D Expenses for the twelve months ending Sep 30, 2026 was $429.98M, up 41.2% year over year. For fiscal 2025 it was $316.57M, up 31.8% from the year before. The highest annual figure on record is $316.57M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $316.57M | +31.8% |
| FY2024 | Dec 31, 2024 | $240.25M | +27.1% |
| FY2023 | Dec 31, 2023 | $189.08M | +15.1% |
| FY2022 | Dec 31, 2022 | $164.25M | +19.9% |
| FY2021 | Dec 31, 2021 | $137.02M | +120.6% |
| FY2020 | Dec 31, 2020 | $62.11M | +67.1% |
| FY2019 | Dec 31, 2019 | $37.16M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $128.51M | +73.4% |
| Q2 FY2026 | Jun 30, 2026 | $119.48M | +52.4% |
| Q1 FY2026 | Mar 31, 2026 | $98.16M | +22.3% |
| Q4 FY2025 | Dec 31, 2025 | $83.83M | +16.7% |
| Q3 FY2025 | Sep 30, 2025 | $74.09M | +22.7% |
| Q2 FY2025 | Jun 30, 2025 | $78.39M | +32.4% |
| Q1 FY2025 | Mar 31, 2025 | $80.26M | +64.4% |
| Q4 FY2024 | Dec 31, 2024 | $71.82M | +35.6% |
| Q3 FY2024 | Sep 30, 2024 | $60.41M | +25.5% |
| Q2 FY2024 | Jun 30, 2024 | $59.20M | +29.4% |
| Q1 FY2024 | Mar 31, 2024 | $48.82M | +15.6% |
| Q4 FY2023 | Dec 31, 2023 | $52.97M | +22.8% |
| Q3 FY2023 | Sep 30, 2023 | $48.12M | +9.7% |
| Q2 FY2023 | Jun 30, 2023 | $45.77M | +10.8% |
| Q1 FY2023 | Mar 31, 2023 | $42.23M | +17.5% |
| Q4 FY2022 | Dec 31, 2022 | $43.13M | +14.9% |
| Q3 FY2022 | Sep 30, 2022 | $43.88M | +14.5% |
| Q2 FY2022 | Jun 30, 2022 | $41.29M | +17.2% |
| Q1 FY2022 | Mar 31, 2022 | $35.94M | +38.4% |
| Q4 FY2021 | Dec 31, 2021 | $37.53M | +84.0% |
| Q3 FY2021 | Sep 30, 2021 | $38.31M | +142.8% |
| Q2 FY2021 | Jun 30, 2021 | $35.22M | +154.9% |
| Q1 FY2021 | Mar 31, 2021 | $25.96M | +114.3% |
| Q4 FY2020 | Dec 31, 2020 | $20.39M | +83.9% |
| Q3 FY2020 | Sep 30, 2020 | $15.78M | +39.5% |
| Q2 FY2020 | Jun 30, 2020 | $13.82M | – |
| Q1 FY2020 | Mar 31, 2020 | $12.12M | – |
| Q4 FY2019 | Dec 31, 2019 | $11.09M | – |
| Q3 FY2019 | Sep 30, 2019 | $11.31M | – |
See a number that looks wrong?